Fusion Polypeptide RBD-NTD Dimer for Broad SARS-CoV-2 Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against SARS CoV-2 face challenges in ensuring effectiveness, production costs, and the need for multiple vaccines to address various variants, highlighting the need for innovative therapeutic options.
Innovation Solution
Development of fusion polypeptides comprising the SARS CoV-2 Spike protein receptor binding domain dimer (RBD dimer) fused to a portion of the N-terminal domain (NTD) using non-immunogenic amino acid linkers, which are effective in eliciting both humoral and cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple different vaccines are developed to address various SARS CoV-2 variants, then the adaptability and coverage of vaccine protection is improved, but the device complexity and manufacturing complexity increase
Solution Approach 1:
The patent employs a universal vaccine platform using fusion polypeptides that can target multiple SARS CoV-2 variants. The fusion polypeptide design incorporates conserved epitopes from different viral strains, allowing a single vaccine platform to provide broad-spectrum protection against multiple variants without requiring separate vaccine development for each strain.
Solution Approach 2:
The vaccine utilizes composite fusion polypeptides that combine multiple antigenic domains from SARS CoV-2 variants into a single molecular structure. This composite approach integrates conserved regions from different variants (such as RBD from one variant and NTD from another) to create a multi-functional antigen that elicits broad immune responses against various strains.
2Productivity
If candidate molecules are produced at appropriate levels and in the appropriate form for therapeutic use, then the productivity and efficacy are improved, but the manufacturing precision and cost-effectiveness worsen
Solution Approach 1:
The patent employs recombinant DNA technology to create copies of the fusion polypeptide gene in expression vectors, which are then introduced into host cells for规模化 production. This copying approach allows for the generation of multiple identical copies of the therapeutic molecule through cellular replication and protein expression, enabling cost-effective large-scale manufacturing.
Solution Approach 2:
The fusion polypeptide is designed with self-assembling properties that allow it to automatically form its functional structure upon expression in host cells, eliminating the need for complex post-translational modification or assembly steps. The molecule performs its own folding and structural organization, reducing manufacturing complexity and cost.
Data Source
AI summary
Disclosed herein are fusion polypeptides comprising at least one peptide domain from a severe acute respiratory syndrome coronavirus (SARS CoV-2) spike protein (S-protein), polynucleotides encoding such fusion polypeptides, methods of making such polypeptides and polynucleotides, pharmaceutical compositions and vaccines comprising such polypeptides or polynucleotides, and methods of using such polypeptides and/or polynucleotides for the treatment or prevention of SARS CoV-2 infection in a subject.